BioPorto A/S to Webcast with HCA and Nordnet regarding the ongoing rights issue

June 9, 2023
News release

BioPorto A/S to Webcast with HCA and Nordnet regarding the ongoing rights issue

COPENHAGEN, DENMARK and BOSTON, MA, USA, June 9, 2023, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of acute kidney injury (AKI), announced today that, in connection with the ongoing rights issue described in its recent Announcement, the Company’s management team will host two online investor presentations next week:

• Monday, June 12, 2023 at 12:00 Central European Time via HC Andersen Capital. Investors interested in attending this webcast may register at: https://hca.videosync.fi/2023-06-12-bioporto/register.
  
  
• Tuesday, June 13, 2023 at 14:00 Central European Time via Nordnet. Investors interested in attending this event may register at: https://events.nordnet.dk/webinar/bioporto-nyeaktier-2023/.
  
  

For investor inquiries, please contact:
Tim Eriksen, EU Investor Relations, Zenith Advisory, 
[phone], [e-mail]

About BioPorto

BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.

The Company’s flagship product, The NGAL Test^TM, is designed to aid in the risk assessment of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality if not identified and treated early. With the aid of The NGAL Test, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The NGAL Test is CE marked and registered in a number of countries worldwide.